MS
TEVA icon

Maven Securities’s Teva Pharmaceuticals TEVA Stock Holding History

Maven Securities’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24,600
Closed -$251K – 1194
2023
Q3 		$251K Buy
+24,600
New +$229K ﹤0.01% 992

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Maven Securities's TEVA Position: Q4 2023 in Review

Maven Securities sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 13,177 shares — an estimated $134K sold.

Maven Securities first reported a position in TEVA in Q4 2016 and held it in 3 quarters. The position peaked at $134K in Q3 2023. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Maven Securities reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Maven Securities sold 13,177 Teva Pharmaceuticals shares in Q4 2023, an estimated $134K.
  • Maven Securities first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Maven Securities's Teva Pharmaceuticals position peaked at $134K in Q3 2023.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Maven Securities's 13F filing for Q4 2023, filed 12 Feb 2024.